Aloysius Onwuka, MD
Internal Medicine · Villas, NJNPI 1659328987
Payments from drug & device makers
Across 286 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$859
- Lilly USA, LLC$416
- Teva Pharmaceuticals USA, Inc.$312
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$304
- Novo Nordisk$300
- Bayer$291
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$120%
- Food & beverage$4,78998%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $859 |
| Lilly USA, LLC | 30 | $416 |
| Teva Pharmaceuticals USA, Inc. | 7 | $312 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $304 |
| Novo Nordisk | 11 | $300 |
| Bayer | 13 | $291 |
| Amarin Pharma, Inc. | 24 | $279 |
| Astellas Pharma US Inc | 13 | $246 |
| Avanir Pharmaceuticals, Inc. | 10 | $236 |
| Otsuka America Pharmaceutical, Inc. | 7 | $231 |
| Sunovion Pharmaceuticals Inc. | 20 | $183 |
| Nestle Healthcare Nutrition Inc. | 11 | $143 |
| Philips North America LLC | 9 | $135 |
| Pfizer | 9 | $127 |
| Sun Pharmaceutical Industries Inc. | 9 | $121 |
| Kowa Pharmaceuticals America, Inc. | 7 | $97 |
| Novartis | 6 | $82 |
| AbbVie(2 entities) | 5 | $66 |
| GSK | 4 | $51 |
| Neurocrine Biosciences, Inc. | 3 | $50 |
| Johnson & Johnson | 4 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Neurelis, Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 2 | $29 |
| Acadia Pharmaceuticals Inc | 2 | $28 |
| Biogen | 2 | $28 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Eisai Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| UCB, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Urovant Sciences Inc | 1 | $12 |
| Acorda Therapeutics, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,872 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 901 | $376,431 |
| JardianceEmpagliflozin | 109 | $79,147 |
| XifaxanRifaximin | 53 | $77,578 |
| TrulicityDulaglutide | 90 | $75,578 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $68,491 |
| FarxigaDapagliflozin Propanediol | 68 | $68,026 |
| TradjentaLinagliptin | 141 | $53,497 |
| XareltoRivaroxaban | 124 | $51,811 |
| MyrbetriqMirabegron | 109 | $38,048 |
| JanuviaSitagliptin Phosphate | 51 | $35,533 |
| EntrestoSacubitril/Valsartan | 43 | $35,043 |
| MounjaroTirzepatide | 19 | $30,937 |
| Glatiramer Acetate | 13 | $29,547 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 124 | $27,185 |
| RexultiBrexpiprazole | 29 | $23,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $127 | $376,431901 claims |
| Boehringer IngelheimJardiance, Tradjenta | $14 | $132,644250 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $416 | $106,515109 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $859 | $95,833109 claims |
| GSKTrelegy Ellipta, Arexvy, Incruse Ellipta | $51 | $88,531156 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $304 | $77,57853 claims |
| Johnson & JohnsonXarelto | $48 | $51,811124 claims |
| AbbVieCreon, Restasis, Linzess | $66 | $42,39469 claims |
| Astellas Pharma US IncMyrbetriq | $246 | $38,048109 claims |
| NovartisEntresto | $82 | $35,04343 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $231 | $23,85129 claims |
| Novo NordiskOzempic | $300 | $19,65022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Villas
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.